Plant ID: NPO6536
Plant Latin Name: Marrubium velutinum
Taxonomy Genus: Marrubium
Taxonomy Family: Lamiaceae
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
China
ACHE; | |
CSNK2A1; | |
CA2; CA12; CA7; | |
ESR2; | |
HSD17B1; ACLY; | |
THPO; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | ACLY | ATP-citrate synthase | P53396 | CHEMBL3720 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.987E-12 | 6.350E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.075E-10 | 7.805E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.254E-08 | 4.463E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.626E-08 | 6.074E-05 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.904E-08 | 9.396E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.372E-07 | 1.757E-04 | CA12, CA2, CA7 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.000E-07 | 4.839E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.322E-07 | 5.794E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 7.803E-07 | 7.388E-04 | CYP19A1, CYP1A2, CYP3A4 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.463E-06 | 1.138E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.463E-06 | 1.138E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.134E-06 | 1.408E-03 | CA12, CA2, CA7 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.924E-06 | 1.721E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.924E-06 | 1.721E-03 | CYP1A2, CYP3A4 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.944E-06 | 2.147E-03 | CA12, CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.872E-06 | 2.588E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 7.305E-06 | 3.418E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.305E-06 | 3.418E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.022E-05 | 4.281E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.363E-05 | 5.494E-03 | CYP1A1, CYP1A2 |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.188E-05 | 8.214E-03 | CA2, CA7 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.344E-12 | 4.570E-11 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.396E-08 | 5.773E-07 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.590E-07 | 1.569E-06 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.546E-07 | 1.731E-06 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.657E-06 | 1.505E-05 | CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.846E-07 | 1.569E-06 | CA12, CA2, CA7 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.163E-05 | 5.646E-05 | CYP1A2, CYP1A1, CYP3A4 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.089E-04 | 4.628E-04 | ACLY, HSD17B1, CYP1A2, CYP1A1, CYP3A4, CYP19A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.039E-03 | 3.400E-03 | CYP1A2, CYP3A4 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.828E-04 | 6.904E-04 | CYP1A2, CYP3A4 |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.100E-03 | 3.400E-03 | CA2, CYP3A4 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 3.495E-03 | 9.904E-03 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
NA: NA | Edema | NA | CA2; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; ACHE; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |